Venus Medtech (Hangzhou) Inc.
HKSE: 2500.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Hou-Sen Lim MEng.
- Employees
- 691
- Headquarters
- Hangzhou, China
- IPO year
- 2019
- Market cap
- HK$771.8M
- Website
- https://www.venusmedtech.com
Loading 2500…
Loading profile data…Frequently asked questions about 2500
What does Venus Medtech (Hangzhou) Inc. (2500.HK) do?
Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the...
Where does 2500.HK trade?
Venus Medtech (Hangzhou) Inc. (2500.HK) trades on the Hong Kong Stock Exchange.
What sector is 2500.HK in?
Venus Medtech (Hangzhou) Inc. (2500.HK) operates in the Healthcare sector, specifically in the Medical - Devices industry.
Who is the CEO of Venus Medtech (Hangzhou) Inc.?
Hou-Sen Lim MEng. is the chief executive officer of Venus Medtech (Hangzhou) Inc. (2500.HK).
Where is Venus Medtech (Hangzhou) Inc. headquartered?
Venus Medtech (Hangzhou) Inc. is headquartered in China.
Does 2500.HK pay a dividend?
Venus Medtech (Hangzhou) Inc. (2500.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 2500.HK go public?
Venus Medtech (Hangzhou) Inc. (2500.HK) completed its initial public offering in 2019.